107027-34-9Relevant articles and documents
Phenylquinoline transient receptor potential vanilloid 1 antagonists for the treatment of pain: Discovery of 1-(2-phenylquinoline-4-carbonyl)-N-(4-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide
Liao, Chen,Liu, Yan,Liu, Chunxia,Zhou, Jiaqi,Li, Huilan,Wang, Nasi,Li, Jieming,Liu, Taiyu,Ghaleb, Hesham,Huang, Wenlong,Qian, Hai
, p. 845 - 854 (2018/01/10)
Reported herein is the design, synthesis, and pharmacologic characterization of a class of TRPV1 antagonists constructed on a phenylquinoline platform that evolved from Cinchophen lead. This design composes three sections: a phenylquinoline headgroup attached to an aliphatic carboxamides, which is tethered at a phenyl tail group. Optimization of this design led to the identification of 37, comprising a pyrrolidine linker and a trifluoromethyl–phenyl tail. In the TRPV1 functional assay, using cells expressed hTRPV1, 37 antagonized capsaicin-induced Ca2+ influx, with an IC50 value of 10.2 nM. In the complete mice analgesic model, 37 exhibited better antinociceptive activity than the positive control BCTC in diverse pain models. All of these results suggested that 37 could be considered as a lead candidate for the further development of antinociceptive drugs.
Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase
Boa, Andrew N.,Canavan, Shane P.,Hirst, Paul R.,Ramsey, Christopher,Stead, Andrew M.W.,McConkey, Glenn A.
, p. 1945 - 1967 (2007/10/03)
A series of 2-phenyl quinoline-4-carboxylic acid derivatives related to brequinar, an inhibitor of human dihydroorotate dehydrogenase (DHODH), has been prepared and evaluated as inhibitors of DHODH from the malaria parasite Plasmodium falciparum. Brequinar was essentially inactive against PfDHODH (IC50 880 μM) whereas several members of the series inhibited PfDHODH. Unexpectedly, replacement of the carboxylic acid required for brequinar to inhibit hDHODH was not essential in the diisopropylamides that inhibited PfDHODH.
N-type calcium channel antagonists for the treatment of pain
-
, (2008/06/13)
Compounds useful for the treatment of pain in accord with the following structural diagram, wherein R1, R2, R3, R4 and R5 are any of a number of groups as defined in the specification, A and D are as
Substituted quinoline derivatives and pharmaceutical compositions thereof
-
, (2008/06/13)
The novel class of substituted quinolines represented by the general formula (I): STR1 where each of R1 and R2 separately represents H or up to three of the groups lower alkyl, halogen, CF3, CN, SO2 CH3, NO2, OH, NH2, NHSO2 R3, NHCOOR3, OR3, SR3, NHR3 or NR3 R3 (where R3 is lower alkyl optionally substituted with hydroxy, amino or ether functions), and each of R1 and R2 may additionally separately represent the substitution of an aza (--N=) group for one or two of the methine (--CH=) groups in each of the carbocyclic rings, and R1 may also represent, at positions 2', 3' or 4' only, a phenyl ring optionally further substituted with lower alkyl, halogen, CF3, CN, SO2 CH3, NO2, OH, NH2, NHCOR3, NHCOOR3, OR3, SR3, NHR3 or NR3 R3 (where R3 is lower alkyl optionally substituted with hydroxy, amino or ether functions); Y represents C(NH)NH2, NHC(NH)NH2 or NR4 R5, where each of R4 and R5 is H or lower alkyl optionally substituted with hydroxy, amino or ether functions, or R4 and R5 together with the nitrogen atom form a heterocyclic ring; and n is from 2 to 6; and the acid addition salts and 1-N-oxides thereof, possess antibacterial and antitumor properties.
Potential antitumor agents. 57. 2-Phenylquinoline-8-carboxamides as 'minimal' DNA-intercalating antitumor agents with in vivo solid tumor activity
Atwell,Baguley,Denny
, p. 396 - 401 (2007/10/02)
A series of phenyl-substituted derivatives of the 'minimal' DNA-intercalating agent N-[2-(dimethylamino)-ethyl]-2-phenylquinoline-8-carboxamide (1) have been synthesized and evaluated for in vivo antitumor activity, in a continuing search for active compo